GO:0032685 negative regulation of granulocyte macrophage colony-stimulating factor production: Immune Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032685 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of granulocyte macrophage colony-stimulating factor (GM-CSF) production.
• GM-CSF production is controlled by both positive and negative regulatory elements in its promoter, as shown in endothelial cells and T-cell lines.
• Cell-type-restricted negative regulatory activity of the human GM-CSF gene was characterized in fibroblasts and other non-hematopoietic cells.
• The AML1-related transcription factor PEBP2 can both activate and repress GM-CSF promoter activity, illustrating context-dependent negative regulation.
• GM-CSF itself can feed back to negatively regulate early IL-10-mediated responses, linking this GO term to immune homeostasis.
• Dysregulation of GM-CSF production is implicated in inflammatory diseases, cancer progression, and myocardial infarction-associated fibrosis.
Description
Granulocyte macrophage colony-stimulating factor (GM-CSF) is a cytokine that drives the differentiation, survival, and activation of myeloid cells. Its production must be tightly controlled because excessive or prolonged GM-CSF signaling can amplify inflammation and tissue damage. GO:0032685, negative regulation of granulocyte macrophage colony-stimulating factor production, captures the biological processes that restrain GM-CSF synthesis at the transcriptional and post-transcriptional levels. Understanding this term is essential for researchers studying immune homeostasis, inflammatory disease, and cancer immunology, where GM-CSF levels influence disease progression and therapeutic outcomes. Mechanistically, negative regulation of GM-CSF production often involves cis-acting promoter elements and trans-acting factors that repress transcription. Early studies identified both positive and negative regulatory elements in the GM-CSF promoter of normal endothelial cells, demonstrating that cell-type-specific repressors can override activating signals. Similarly, the AML1-related transcription factor PEBP2 was shown to positively and negatively regulate GM-CSF promoter activity depending on cellular context. A cell-type-restricted negative regulatory activity was also mapped within the human GM-CSF gene, highlighting that repression is not universal but tailored to specific cell lineages. Beyond transcriptional control, GM-CSF itself can participate in negative feedback loops. For example, GM-CSF negatively regulates early IL-10-mediated responses, suggesting that it can shape the cytokine milieu by limiting anti-inflammatory signals. In disease settings, dysregulated GM-CSF production contributes to maladaptive fibroblast-myeloid crosstalk after myocardial infarction, enhances pro-inflammatory macrophage responses to Pseudomonas aeruginosa, and correlates with poor survival in gastric cancer through GM-CSF-activated neutrophils. Thus, GO:0032685 is a critical node connecting cytokine regulation to human pathophysiology.
negative regulation of granulocyte macrophage colony-stimulating factor production At A Glance
| GO ID | GO:0032685 |
|---|---|
| GO term | negative regulation of granulocyte macrophage colony-stimulating factor production |
| Ontology | biological_process |
| Synonym | negative regulation of GM-CSF production; inhibition of granulocyte macrophage colony-stimulating factor production; downregulation of granulocyte macrophage colony-stimulating factor production |
| Major function | Restrains GM-CSF cytokine production to prevent excessive myeloid activation and inflammation |
| Related processes | Transcriptional repression, mRNA stability, cytokine secretion control |
| Key regulators | PEBP2/AML1, cell-type-restricted repressors, IL-10 feedback |
| Disease relevance | Inflammation, cancer progression, myocardial infarction, infection |
What Is GO:0032685?
GO:0032685, negative regulation of granulocyte macrophage colony-stimulating factor production, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of GM-CSF production. This includes transcriptional repression, mRNA destabilization, and inhibition of protein secretion, as long as the outcome is reduced GM-CSF output. The term is a biological process and is distinct from positive regulation of GM-CSF production, which would enhance cytokine synthesis.
Why Is negative regulation of granulocyte macrophage colony-stimulating factor production Important in Cell Biology?
Negative regulation of GM-CSF production is essential for preventing runaway inflammation and maintaining immune balance. GM-CSF amplifies myeloid cell recruitment and activation, so its production must be tightly controlled to avoid tissue damage. This GO term is important because defects in GM-CSF repression can contribute to chronic inflammatory diseases, cancer progression, and impaired tissue repair after injury. Understanding the mechanisms of negative regulation provides opportunities for therapeutic intervention in conditions where GM-CSF is overproduced.
• Prevents excessive myeloid cell activation and inflammation by limiting GM-CSF availability.
• Controls immune homeostasis through feedback inhibition of IL-10-mediated responses.
• Regulates tissue repair after myocardial infarction by modulating fibroblast-myeloid crosstalk.
• Influences cancer progression, as GM-CSF-activated neutrophils correlate with poor survival in gastric cancer.
• Modulates host response to infection, including Pseudomonas aeruginosa-induced inflammation.
• Provides cell-type-specific control of cytokine production via promoter regulatory elements.
• Involves transcription factors such as PEBP2 that can both activate and repress GM-CSF.
• Offers targets for anti-inflammatory therapies in autoimmune and chronic inflammatory diseases.
• Helps explain how non-hematopoietic cells restrict GM-CSF production.
• Connects cytokine regulation to broader processes like angiogenesis and tumor microenvironment remodeling.
What Happens During negative regulation of granulocyte macrophage colony-stimulating factor production?
Transcriptional repression via promoter elements
In simple terms: The GM-CSF gene has DNA switches that can be turned off by repressor proteins.
Negative regulation of GM-CSF production frequently occurs at the transcriptional level through cis-acting negative regulatory elements in the GM-CSF promoter. In normal endothelial cells, both positive and negative regulatory elements control GM-CSF production, allowing fine-tuned expression. A cell-type-restricted negative regulatory activity was mapped within the human GM-CSF gene, demonstrating that specific DNA sequences can repress transcription in a lineage-specific manner. These elements recruit trans-acting factors that interfere with activator binding or recruit co-repressors.
Role of transcription factors like PEBP2/AML1
In simple terms: Some transcription factors can act as both gas and brake for the GM-CSF gene.
The AML1-related transcription factor PEBP2 can positively and negatively regulate GM-CSF promoter activity depending on context. This dual function illustrates how the same factor can switch from activator to repressor based on cellular signals or partner proteins. Negative regulation by PEBP2 may involve competition with co-activators or recruitment of repressive complexes at the GM-CSF promoter.
Cell-type-specific repressor activity
In simple terms: Different cell types have different brakes for GM-CSF production.
Negative regulation of GM-CSF production is not uniform across cell types. Fraser et al. characterized a cell-type-restricted negative regulatory activity of the human GM-CSF gene, showing that fibroblasts and other non-hematopoietic cells can actively repress GM-CSF transcription. This specificity ensures that GM-CSF is produced only when and where needed, preventing inappropriate myeloid activation in tissues that normally do not express this cytokine.
Feedback inhibition by cytokines such as IL-10
In simple terms: GM-CSF can trigger signals that later shut down its own production or related inflammatory responses.
GM-CSF negatively regulates early IL-10-mediated responses, indicating a feedback mechanism that can limit anti-inflammatory signals. This cross-regulation suggests that GM-CSF production is embedded in a cytokine network where negative regulation helps balance pro- and anti-inflammatory outputs. Such feedback loops are critical for resolving inflammation and preventing chronic immune activation.
Post-transcriptional and secretion control
In simple terms: Even after the gene is turned on, the cell can still reduce GM-CSF by degrading its mRNA or blocking release.
Although transcriptional repression is well documented, negative regulation of GM-CSF production can also occur post-transcriptionally. mRNA stability and protein secretion are potential control points, though specific mechanisms in the context of GO:0032685 are less characterized in the cited literature. The QuickGO definition includes any process that reduces the frequency, rate, or extent of GM-CSF production, encompassing these additional layers.
Key Genes Involved in GO:0032685 negative regulation of granulocyte macrophage colony-stimulating factor production
The following genes and proteins have been experimentally linked to the regulation of GM-CSF production, including negative regulatory roles.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CSF2 | Encodes GM-CSF cytokine | Target of negative regulation; promoter contains negative regulatory elements |
| PEBP2 (AML1/RUNX1) | Transcription factor that can repress GM-CSF promoter | Demonstrates context-dependent negative regulation |
| IL10 | Anti-inflammatory cytokine | GM-CSF negatively regulates early IL-10-mediated responses |
| CD2 | T/NK cell receptor | Modulates GM-CSF production in natural killer cells |
| IL2RB (CD122, p75) | IL-2 receptor subunit | Regulates GM-CSF production in NK cells |
| SIPA1 | Signal-induced proliferation-associated 1 | Drives fibroblast-myeloid axis after myocardial infarction, influencing GM-CSF |
| B7-H4 (VTCN1) | Immune checkpoint ligand | Expressed by GM-CSF-activated neutrophils; correlates with gastric cancer progression |
| IFNG | Interferon-gamma | Enhances pro-inflammatory macrophage responses to Pseudomonas aeruginosa with GM-CSF |
| NF-κB | Transcription factor | Often involved in GM-CSF promoter activation; negative regulators may antagonize it |
| AP-1 | Transcription factor | Contributes to GM-CSF promoter activity; repression may involve interference |
| NFAT | Transcription factor | Regulates GM-CSF in T cells; negative regulation may target NFAT sites |
| CEBPB | Transcription factor | Binds GM-CSF promoter; potential target for repression |
| SP1 | Transcription factor | Constitutive factor at GM-CSF promoter; negative regulators may displace it |
| GATA2 | Transcription factor | Lineage-specific regulator that may repress GM-CSF in non-hematopoietic cells |
| PU.1 (SPI1) | Ets transcription factor | Activates GM-CSF in myeloid cells; negative regulation may oppose PU.1 |
| RUNX1 | Transcription factor | Same as PEBP2/AML1; dual role in GM-CSF regulation |
| STAT3 | Signal transducer | IL-10 signaling via STAT3 may feedback to limit GM-CSF |
How Is negative regulation of granulocyte macrophage colony-stimulating factor production Regulated?
Negative regulation of GM-CSF production is controlled by a combination of transcriptional repressors, cell-type-specific factors, and cytokine feedback loops. Promoter elements that bind repressive complexes can override activating signals from NF-κB, AP-1, and NFAT. Cell-type-restricted negative regulatory activity ensures that GM-CSF is not produced in inappropriate tissues. Additionally, GM-CSF itself can negatively regulate early IL-10-mediated responses, creating a feedback mechanism that modulates the inflammatory milieu. These layers of regulation allow precise control of GM-CSF levels during immune responses and tissue repair.
negative regulation of granulocyte macrophage colony-stimulating factor production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CSF2 | Inflammatory diseases, cancer | CSF2 promoter-reporter knockout cell lines |
| SIPA1 | Myocardial infarction | Sipa1 knockout mice or cardiomyocyte-specific KO |
| IL10 | Autoimmunity, inflammation | IL10 knockout macrophages with GM-CSF stimulation |
| VTCN1 (B7-H4) | Gastric cancer progression | GM-CSF-activated neutrophil co-culture with cancer cells |
| IFNG | Pseudomonas aeruginosa infection | IFN-γ-treated macrophage KO models |
Inflammatory and infectious diseases
GM-CSF enhances pro-inflammatory macrophage responses to Pseudomonas aeruginosa infection, and negative regulation of its production is critical to prevent excessive tissue damage. Dysregulated GM-CSF production can exacerbate inflammation in chronic infections and autoimmune conditions. The balance between positive and negative regulatory elements determines the extent of myeloid activation and subsequent pathology.
Cancer progression
GM-CSF-activated neutrophils express B7-H4, which correlates with gastric cancer progression and poor patient survival. Negative regulation of GM-CSF production may limit the generation of immunosuppressive neutrophils in the tumor microenvironment. Understanding how GM-CSF is repressed could inform strategies to modulate anti-tumor immunity.
Cardiovascular disease and tissue repair
After myocardial infarction, Sipa1 drives a maladaptive fibroblast-myeloid axis that involves GM-CSF signaling. Negative regulation of GM-CSF production may protect against adverse remodeling by limiting myeloid cell recruitment and fibrosis. Targeting this pathway could improve outcomes after cardiac injury.
Immune homeostasis and autoimmunity
GM-CSF negatively regulates early IL-10-mediated responses, linking its production to the balance between pro- and anti-inflammatory cytokines. Defects in negative regulation of GM-CSF could contribute to autoimmunity by tipping the balance toward persistent inflammation. Modulating this pathway may offer therapeutic avenues for autoimmune diseases.
From negative regulation of granulocyte macrophage colony-stimulating factor production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene repress GM-CSF transcription? | CRISPR knockout of the gene in GM-CSF-expressing cells followed by ELISA |
| Does a point mutation in a promoter element affect repression? | Point mutation knock-in of the GM-CSF promoter in reporter cell lines |
| Does a repressor bind the GM-CSF promoter? | Knock-in of tagged repressor (e.g., HA-PEBP2) for ChIP-seq |
| Does overexpression of a repressor reduce GM-CSF? | Overexpression of candidate repressor in primary macrophages |
| Is the negative regulatory element cell-type specific? | Knockout of the element in fibroblasts vs. endothelial cells |
| Does GM-CSF feedback regulate IL-10? | GM-CSF knockout or overexpression in IL-10 reporter cells |
How to Study the negative regulation of granulocyte macrophage colony-stimulating factor production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Luciferase reporter assay | Transcriptional activity of GM-CSF promoter | Mapping negative regulatory elements |
| ELISA | GM-CSF protein concentration | Confirming negative regulation at protein level |
| ChIP-qPCR | Binding of repressors to GM-CSF promoter | Validating direct repression |
| RNA-seq | GM-CSF mRNA levels and transcriptome changes | Global effects of repressor knockout |
| CRISPR screen | Genes affecting GM-CSF production | Discovery of novel negative regulators |
| Flow cytometry | Intracellular GM-CSF in single cells | Cell-type-specific regulation |
| Co-culture assays | Myeloid cell activation by GM-CSF | Functional impact of negative regulation |
| Western blot | Repressor protein expression | Correlating repressor levels with GM-CSF output |
Transcriptional reporter assays
GM-CSF promoter-reporter constructs can be used to map negative regulatory elements and test candidate repressors. Luciferase or GFP reporters driven by the GM-CSF promoter with or without specific mutations allow quantification of transcriptional repression in different cell types.
Cytokine quantification by ELISA and Luminex
Measuring GM-CSF protein levels in culture supernatants or serum is essential to confirm negative regulation. ELISA and multiplex assays provide sensitive detection of GM-CSF and other cytokines, enabling researchers to link transcriptional changes to actual protein output.
Chromatin immunoprecipitation (ChIP) and ChIP-seq
ChIP assays can determine whether candidate repressors bind to the GM-CSF promoter in vivo. ChIP-seq provides genome-wide mapping of binding sites, helping to identify direct targets and cooperative repressive complexes.
CRISPR-based genetic screens
Pooled CRISPR knockout or activation screens can identify genes that negatively regulate GM-CSF production. By coupling GM-CSF reporter expression to cell sorting or survival, researchers can discover novel repressors and validate them in secondary assays.
How CRISPR Can Be Used to Study GO:0032685 negative regulation of granulocyte macrophage colony-stimulating factor production
Knockout
CRISPR knockout of candidate repressor genes (e.g., PEBP2, cell-type-specific factors) can test whether they are required for negative regulation of GM-CSF production. Loss of a repressor should lead to increased GM-CSF mRNA and protein, as measured by RNA-seq and ELISA.
Point Mutation
Point mutations in the GM-CSF promoter or in repressor binding sites can be introduced using CRISPR base editing or homology-directed repair. These models help define the exact DNA sequences required for negative regulation and can reveal disease-associated variants.
Knock-in
Knock-in of tagged repressors (e.g., HA-PEBP2) or reporter genes (e.g., GFP under the GM-CSF promoter) allows real-time monitoring of negative regulation. Tagged knock-ins facilitate ChIP-seq and imaging studies to localize repressors at the GM-CSF locus.
Overexpression
Overexpression of candidate repressors via CRISPR activation or lentiviral delivery can suppress GM-CSF production. This approach is useful for validating sufficiency of a repressor and for testing therapeutic potential in inflammatory models.
How EDITGENE Supports negative regulation of granulocyte macrophage colony-stimulating factor production Research
Researchers studying negative regulation of granulocyte macrophage colony-stimulating factor production-related genes often need to determine whether a candidate gene is causally involved in repressing GM-CSF or is merely correlated with changes in cytokine levels. Establishing causality requires precise genetic manipulation, such as knockout, point mutation, knock-in, or overexpression, followed by functional readouts like ELISA, reporter assays, and RNA-seq. EDITGENE provides end-to-end CRISPR services to accelerate these discoveries.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of granulocyte macrophage colony-stimulating factor production research.
Frequently Asked Questions About negative regulation of granulocyte macrophage colony-stimulating factor production
What is GO:0032685?
GO:0032685 is the Gene Ontology term for negative regulation of granulocyte macrophage colony-stimulating factor production, describing any process that stops, prevents, or reduces GM-CSF production.
What genes are involved in negative regulation of GM-CSF production?
Key genes include CSF2 (encoding GM-CSF), PEBP2/AML1 (RUNX1), IL10, and cell-type-specific repressors that bind the GM-CSF promoter.
How is GM-CSF production negatively regulated?
It is regulated by transcriptional repressors binding to promoter elements, cell-type-restricted negative regulatory activity, and cytokine feedback loops such as GM-CSF-mediated inhibition of IL-10 responses.
Why is negative regulation of GM-CSF important?
It prevents excessive myeloid activation and inflammation, and its dysregulation is linked to inflammatory diseases, cancer progression, and impaired tissue repair.
What diseases are associated with dysregulated GM-CSF production?
Diseases include chronic inflammation, gastric cancer, myocardial infarction, and infections such as Pseudomonas aeruginosa.
What cell types regulate GM-CSF production?
Endothelial cells, fibroblasts, T cells, natural killer cells, and macrophages all regulate GM-CSF production through positive and negative elements.
How can I study negative regulation of GM-CSF production?
Use CRISPR knockout, point mutation, knock-in, or overexpression models combined with ELISA, reporter assays, ChIP, and RNA-seq.
What is the role of PEBP2 in GM-CSF regulation?
PEBP2 (AML1/RUNX1) can both activate and repress GM-CSF promoter activity, demonstrating context-dependent negative regulation.
Does GM-CSF feedback regulate IL-10?
Yes, GM-CSF negatively regulates early IL-10-mediated responses, indicating a feedback loop that modulates inflammation.
What CRISPR models are available for studying GM-CSF regulation?
EDITGENE offers knockout, point mutation, knock-in, overexpression, and library screening services to study genes controlling GM-CSF production.
Conclusion
GO:0032685, negative regulation of granulocyte macrophage colony-stimulating factor production, is a critical biological process that restrains GM-CSF synthesis to maintain immune homeostasis. Research has identified promoter elements, transcription factors like PEBP2, cell-type-specific repressors, and cytokine feedback loops as key mechanisms. Dysregulation of this process contributes to inflammatory diseases, cancer, and cardiovascular pathology. Continued investigation using CRISPR models and functional assays will uncover new therapeutic targets for modulating GM-CSF in disease.
References
- 1. Ko S et al.. 2025. Sipa1 Drives a Maladaptive Fibroblast-Myeloid Axis After Myocardial Infarction.. Circ Res 137(4):533-547 PMID: 40567222
- 2. Wilbers RH et al.. 2018. Granulocyte-macrophage colony-stimulating factor negatively regulates early IL-10-mediated responses.. Future Sci OA 4(4):FSO288 PMID: 29682323
- 3. Takahashi A et al.. 1995. Positive and negative regulation of granulocyte-macrophage colony-stimulating factor promoter activity by AML1-related transcription factor, PEBP2.. Blood 86(2):607-16 PMID: 7605990
- 4. Levitt LJ et al.. 1991. Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor.. J Clin Invest 88(1):67-75 PMID: 1676038
- 5. Singh S et al.. 2015. Granulocyte-macrophage colony stimulatory factor enhances the pro-inflammatory response of interferon-γ-treated macrophages to Pseudomonas aeruginosa infection.. PLoS One 10(2):e0117447 PMID: 25706389
- 6. Kaushansky K. 1989. Control of granulocyte-macrophage colony-stimulating factor production in normal endothelial cells by positive and negative regulatory elements.. J Immunol 143(8):2525-9 PMID: 2677143
- 7. Shan ZG et al.. 2021. Granulocyte-Macrophage Colony-Stimulating Factor-Activated Neutrophils Express B7-H4 That Correlates with Gastric Cancer Progression and Poor Patient Survival.. J Immunol Res 2021:6613247 PMID: 33763491
- 8. Fraser JK et al.. 1994. Characterization of a cell-type-restricted negative regulatory activity of the human granulocyte-macrophage colony-stimulating factor gene.. Mol Cell Biol 14(3):2213-21 PMID: 8114751
